This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Becker, P. D.
Right arrow Articles by Grinstein, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Becker, P. D.
Right arrow Articles by Grinstein, S.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, May 2007, p. 538-543, Vol. 14, No. 5
1071-412X/07/$08.00+0     doi:10.1128/CVI.00316-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Immune Modulator Adamantylamide Dipeptide Stimulates Efficient Major Histocompatibility Complex Class I-Restricted Responses in Mice{triangledown}

Pablo D. Becker,1,2 Miriam Nörder,1 Carlos A. Guzmán,1* and Saul Grinstein2*

Department of Vaccinology, Helmholtz Centre for Infection Research, Inhoffenstraße 7, D-38124 Braunschweig, Germany,1 Laboratorio de Virología, Hospital de Niños Ricardo Gutiérrez, Gallo 1330, 1425 Buenos Aires, Argentina2

Received 23 August 2006/ Returned for modification 16 October 2006/ Accepted 22 February 2007

Adamantylamide L-alanyl-D-isoglutamine (AdDP) is a synthetic adjuvant which belongs to the family of the desmuramyl peptides. AdDP exerts its adjuvant properties when it is administered either by the parenteral or by the mucosal route, leading to the elicitation of strong humoral responses at both the systemic and the mucosal levels. However, very little is known about the effect of AdDP on cellular immunity. Here we demonstrate that AdDP is able to stimulate cellular responses, which are characterized by the release of gamma interferon by CD8+ T cells when they are restimulated with a major histocompatibility complex class I-restricted peptide and strong in vivo lymphocyte-mediated cytotoxic activity. The capacity of AdDP to stimulate the elicitation of both cellular and humoral adaptive responses makes this adjuvant a promising tool for the development of mucosal vaccine formulations.

* Corresponding author. Mailing address for Carlos A. Guzmán: Department of Vaccinology, Helmholtz Centre for Infection Research, Inhoffenstraße 7, D-38124 Braunschweig, Germany. Phone: 49 531 6181 4600. Fax: 49 531 6181 4699. E-mail: carlos.guzman{at}helmholtz-hzi.de. Mailing address for Saul Grinstein: Laboratorio de Virología, Hospital de Niños Ricardo Gutiérrez, Gallo 1330, 1425 Buenos Aires, Argentina. Phone: 54 11 4964 3118. Fax: 54 11 4962 6770. E-mail: virologia_hnrg{at}yahoo.com.ar

{triangledown} Published ahead of print on 7 March 2007.

Clinical and Vaccine Immunology, May 2007, p. 538-543, Vol. 14, No. 5
1071-412X/07/$08.00+0     doi:10.1128/CVI.00316-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»